Hydroxychloroquine Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
市場對新羥氯奎的需求不斷增長，仿製藥的滲透率預計將顯著增長。例如，諾華國際公司（Novartis International AG）和美國衛生與社會福利部（HHS）於2020年3月進行了一項對照臨床試驗，以評估羥氯奎對冠狀病毒檢測呈陽性的人群的療效。已經開始出貨3000萬次羥氯奎片劑。此外，隨著政府資金的增加，更多的產品批准有望更深入地滲透市場。
The global hydroxychloroquine drugs market studied was anticipated to register a CAGR of nearly 16.8% during the forecast period. Hydroxychloroquine is a safer derivative of chloroquine. Hydroxychloroquine is an immunosuppressive and anti-parasite drug indicated for the treatment or prevention of malaria, although the drug is ineffective for chloroquine-resistant malaria. Hydroxychloroquine is also recommended for autoimmune diseases such as systemic and discoid lupus erythematosus, and rheumatoid arthritis (acute and severe) when other medications fail to work or cannot be used. Broad-spectrum hydroxychloroquine drugs can be used to treat a range of viruses. According to China's Ministry of Science and Technology, hydroxychloroquine is one of the drugs which demonstrated encouraging profile for blocking coronavirus in early clinical trials.
Recently, hydroxychloroquine has attracted attention due to its effectiveness in treating patients with coronavirus disease (COVID 19). Reports from China demonstrated chloroquine could possibly inhibit SARS-CoV-2 in vitro. The drug showed high efficacy in treating the patients with coronavirus disease (COVID 19). Hydroxychloroquine is expected to be a promising potential treatment for the coronavirus disease (COVID 19). The US Food and Drug Administration (FDA) designated hydroxychloroquine for emergency use for treating coronavirus disease (COVID 19).
Increasing demand for novel hydroxychloroquine and rising penetration of generic drugs are estimated to provide a significant boost to the market. For instance, in March 2020, Novartis International AG started the shipping of 30 million doses of hydroxychloroquine tablets to the US Department of Health and Human Services (HHS) for controlled clinical studies to evaluate the effectiveness of hydroxychloroquine in people who have tested positive for coronavirus disease (COVID 19). In addition, increasing product approval is poised to have strong market penetration due to the presence of increased government funding.
Growing patient awareness regarding COVID-19 and the influx of new generics in the global arena are projected to accelerate the adoption of hydroxychloroquine drugs. As per the Johns Hopkins University, as of 15th April 2020, approximately 609,516 people suffered from COVID-19 in the US alone. Increasing awareness regarding disease remittance therapies, rising clinical trials to evaluate the effectiveness of hydroxychloroquine in the treatment of COVID-19 are estimated to promote revenue growth. However, poor healthcare accessibility in low-income countries may restrain the growth of the market.
North America is at the forefront of growth in the region and is also an important revenue contributor in the global arena. Heightened awareness of disease remittance therapies among patients, rising prevalence of RA and COVID-19, and high public and private healthcare spending are stimulating the growth of the region. Moreover, the World Health Organization estimates that by the end of 2040, 54.4 million adults in the country may suffer from rheumatoid arthritis. Moreover, easy access to quality healthcare, favorable reimbursement policies, strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America.
Asia-Pacific is likely to post the fastest market throughout the forecast horizon. Lack of disease awareness in some underdeveloped regions is leading to an expanding base of patients in the region. This, coupled with increasing healthcare spending, presence of key manufacturers, such as Zydus Cadila, Novartis, and Sun Pharmaceuticals, and growing product approvals, is expected to propel the market in APAC. Increasing demand for target drug for disease reversal is poised to augment the regional markets during the forecast period.
Manufacturers offering generic versions dominate the global hydroxychloroquine drugs market. Companies are focusing on building generic chemical entities and innovative molecules to consolidate their foothold. Some of the prominent market participants are DR. REDDY'S LABORATORIES LTD, Laurus Labs Limited, Lupin, Mylan NV, Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc., and Zydus Pharmaceuticals.
The introduction of generic versions and the strong clinical pipeline is anticipated to increase competition in the market. For instance, in April 2020, Zydus Cadila and Ipca Labs have backward integrated HCQ making capability with the aim to increase production capacity by 5-6 times to 70 MT per month thereby, expanding the range of treatment options for the millions of patients living with target diseases.